Core Insights - Exelixis, Inc. (NASDAQ:EXEL) is considered one of the most undervalued stocks on NASDAQ, with Barclays initiating coverage and setting a price target of $40 per share [1] - The company's primary revenue driver, cabozantinib, is expected to see mid-single-digit growth until its patent expiration in 2029 [1] - Barclays forecasts that Exelixis' overall revenue for 2029 will be approximately 8% lower than consensus estimates, primarily due to reduced sales expectations from pipeline products [2] Company Overview - Exelixis, Inc. specializes in developing targeted cancer treatments, focusing on molecular therapies that address difficult-to-treat cancers by targeting specific genomic mutations [4] Pipeline Developments - Zanzalintinib, a key pipeline candidate for Exelixis, has potential to enhance treatments for colorectal cancer and non-clear cell renal carcinoma [3] - However, there are concerns regarding zanzalintinib's ability to advance to earlier treatment lines in colorectal cancer due to a competitive market landscape [3]

Group 1 - Biogen Inc. is considered one of the most undervalued stocks on NASDAQ, with a recent acquisition of Alcyone Therapeutics for an initial cash payment of $85 million and additional milestone payments [1] - The acquisition centers on ThecaFlex DRx, an implantable device aimed at providing chronic medication delivery for patients with neurological illnesses, eliminating the need for repeated lumbar punctures [2] - Following the acquisition, Biogen will oversee the development, production, and marketing of ThecaFlex DRx, with ongoing clinical studies assessing its effectiveness in patients with spinal muscular atrophy using SPINRAZA (nusinersen) [3]

Woodside Energy Group Ltd (NYSE:WDS) is one of the best dividend stocks to buy. As of August 19, Woodside Energy has been holding discussions with potential partners, including Saudi Aramco, which suggests that it could keep as much as 80% of the holding company for its $17.5 billion Louisiana LNG project in the United States. According to CEO Meg O’Neill, Woodside plans to sell 20% to 30% of the Louisiana LNG project, which came with its $900 million acquisition of Tellurian the prior year. There have be ...

Group 1 - Watts Water Technologies, Inc. (NYSE:WTS) is recognized as a strong investment opportunity, with Jim Cramer recommending to "own it" rather than trade it [1] - The company specializes in fluid and energy management systems and products for buildings, including flow control, HVAC, drainage, water reuse, and water quality solutions [1] - For Q2, Watts Water reported non-GAAP earnings of $3.09, exceeding estimates by $0.46, and revenue of $643.7 million, surpassing estimates by $30 million [1] - The company has raised its full-year outlook, projecting reported sales growth of 2% to 5% and organic sales growth from flat to 3% [1] - Expected operating margin is between 17.2% to 17.8%, with adjusted operating margin forecasted between 18.2% and 18.8%, accounting for estimated tariff impacts as of August 6, 2025 [1]

Energy Transfer LP (NYSE:ET) is one of the best value stocks in Goldman Sachs’ portfolio. Energy Transfer is one of the largest and most diversified midstream operators in North America, with an extensive portfolio spanning natural gas, NGLs, crude oil, and refined products. The stock is a strong Buy as per the consensus of analysts, which still indicates more than 34% potential upside, and recent analyst views have been suggesting an optimistic outlook. In fact, on September 11 and 18, analysts from UBS ...

Core Insights - Paysafe Limited (NYSE: PSFE) is recognized as an oversold software stock with a new partnership with CMC Markets aimed at expanding payment options for traders in various global markets [1][2] - The company reported double-digit growth in Q2 2025, driven by its consumer business and innovative product rollouts, achieving 5% organic revenue growth and 12% adjusted EBITDA growth [2] Group 1: Partnership and Market Expansion - Paysafe Limited announced a partnership with CMC Markets to enhance payment options for traders in the European Economic Area, Southeast Asia, the Middle East, and other global markets, excluding the UK and US [1] - Skrill and Neteller will serve as the first digital wallets and alternative payment methods for CMC Markets in the specified regions [1] Group 2: Financial Performance - In Q2 2025, Paysafe Limited experienced double-digit growth, primarily from its consumer business and strong performance from existing customers [2] - The company achieved 5% organic revenue growth and a 12% increase in adjusted EBITDA, excluding the divested direct marketing business [2] - For FY 2025, Paysafe expects revenues to be between $1,710 million and $1,734 million [2]

Group 1 - Carlisle Companies Incorporated (NYSE:CSL) is recognized as one of the 11 Cheap Quarterly Dividend Stocks to buy currently [1] - The company specializes in designing and producing energy-efficient and sustainable products for commercial and residential buildings, with core divisions including Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT) [2] - Growth is driven by energy-efficient innovation, strategic acquisitions, and the Carlisle Operating System, while success is influenced by construction market trends, pricing, and integration of acquisitions [3] Group 2 - On August 7, Carlisle Companies declared a 10% increase in its quarterly dividend to $1.10 per share, marking the 49th consecutive year of dividend growth [4] - As of September 23, the stock has a dividend yield of 1.58% [4]

Core Viewpoint - The Meridian Contrarian Fund reported a strong performance in Q2 2025, with a return of 16.42%, outperforming the Russell 2500 Index and the Russell 2500 Value Index, amidst a significant recovery in the U.S. equity market, which rose 23% during the quarter [1] Group 1: Fund Performance - The U.S. large-cap stocks gained 11.1% in Q2 2025, with growth stocks outperforming value stocks [1] - The Meridian Contrarian Fund's return of 16.42% (net) exceeded the Russell 2500 Index's return of 8.59% and the Russell 2500 Value Index's return of 7.29% [1] Group 2: QuidelOrtho Corporation (NASDAQ:QDEL) - QuidelOrtho Corporation is a diagnostic testing solutions provider, with a one-month return of -7.51% and a 52-week loss of 41.75%, closing at $26.53 per share on September 25, 2025, with a market capitalization of $1.802 billion [2] - The Meridian Contrarian Fund invested in QuidelOrtho following its merger with Ortho Clinical Diagnostics, believing it positioned the company for improved growth and margins [3] - Despite the company's earnings being in line with expectations, broader macro concerns affected its stock performance, particularly in the respiratory business and potential funding cuts in government health programs [3] Group 3: Hedge Fund Interest - QuidelOrtho Corporation was held by 31 hedge fund portfolios at the end of Q2 2025, a decrease from 32 in the previous quarter [4] - The company reported Q2 revenue of $614 million, down from $637 million in the prior year [4]

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity market showcased a significant recovery during the quarter, rising 23% from low to end the quarter at a record high. U.S. large-cap stocks gained 11.1% in the quarter, and within the large-cap category, growth stocks outperformed value stocks. In this environment, the fund returned 16.42% (net) during the quarter, exceeding ...

Core Insights - Bretton Fund's second quarter 2025 performance was 2.70%, underperforming the S&P 500 Index which returned 10.94% [1] - The fund's underperformance was attributed to a focus on fundamentals rather than market sentiment, particularly in light of the president's easing of tariff threats [1] - Notable underperformers included Berkshire Hathaway and AutoZone, which were categorized as "safe stocks" rather than due to operational issues [1] Company Highlights: UnitedHealth Group Incorporated (NYSE:UNH) - UnitedHealth Group's stock experienced a significant decline of 39.88% over the past 52 weeks, despite a one-month return of 14.31% [2] - As of September 25, 2025, UnitedHealth Group's stock closed at $345.56, with a market capitalization of $312.965 billion [2] - The fund reported that UnitedHealth Group's stock drop contributed to a 2.0% loss for the fund this quarter, indicating a substantial impact on overall performance [3] Financial Performance - UnitedHealth Group reported revenues of nearly $112 billion for the second quarter of 2025, reflecting a 13% increase compared to the same quarter the previous year [4] - The company ranked 18th among the 30 Most Popular Stocks Among Hedge Funds, with 159 hedge fund portfolios holding its stock at the end of the second quarter, up from 139 in the previous quarter [4] Investment Perspective - While UnitedHealth Group is recognized for its potential as an investment, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]